Tagged with Oncology

Thailand Pfizer is now the number one pharmaceuticals company in Thailand. We spoke to Christian Malherbe, Country Lead for IndoChina, which includes Myanmar, Laos, and Cambodia, about how he is making the management structure flatter and continuing to bring new medicines to the region.   In the future, we see our…

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…

UCB UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan for regional expansion through partnerships. Given your patient centricity and UCB’s unique perspective, how would you assess the sectors approach…

cancer Eduardo Payet of INEN outlines the institution’s agenda for preventing advanced stages of cancer and plans to expand oncology services beyond Lima to more remote regions of Peru. What is your assessment of the state of cancer in Peru today? Peru is experiencing a demographic and epidemiological transition as a…

oncology Despite Peru’s sometimes-sluggish development when it comes to healthcare, the progression of cancer prevention and control in recent decades is tremendous. This is particularly important as the number of cancer cases increases by 50,000 annually in Peru. Communicable diseases like infectious diseases, which used to be a predominant cause of death…

biotech SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a cure for cancer’.   Could you please introduce yourself Dr. Moon, and tell us how you became involved with SillaJen? …

R&D The founder of Eriochem discusses his firm’s ambitious technology based on a competitive IP strategy and its exciting research on a radically new oncology platform. Today, Eriochem is a vertically integrated company producing both APIs and final dosage forms; when you started the company, what was the strategy you followed…

oncology In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its go-to-market strategy and has succeeded in positioning itself as a top player in women’s health and primary care, lead by…

Oncology The following graph shows the comparitive spending on oncology products between 2010 and 2012 in the US, the EU, Japan, BRICs and other countries.

development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations.    How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…

Internationalization José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and development in total, Zeltia was finally able to commercialize a novel product.  Would you say that this investment was worth…

Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…